On Monday, Bristol Myers Squibb announced it had selected Generation Park in Houston for a new “state-of-the-art multi-modal manufacturing campus,” according to a news release. The 600,000-square-foot campus represents an expected $2.3 billion investment and the creation of nearly 500 skilled jobs.
The project will also create roughly 2,000 construction and other indirect jobs between 2027 and 2030 as the facility is built.
Bristol Myers Squibb says the Houston campus will be built to adapt and grow with a flexible design that can change as new medicines move through development. Onsite, the pharmaceutical giant will be able to manufacture multiple types of medicines, including small molecules, biologics, and antibody-drug conjugates used to treat a variety of diseases.
The announcement follows Bristol Myers Squibb’s $40 billion, five-year investment in U.S. research, technology and manufacturing. Christopher Boerner, board chair and CEO of Bristol Myers Squibb, said the investment reflects the company’s confidence in America’s leadership in biopharmaceutical innovation.
“As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs,” Boerner said in the release. “Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”
The finalization comes just a few months after filings showed the Fortune 100 pharmaceutical company was considering a 600,000 square-foot, $1 billion manufacturing campus at Houston’s Generation Park.
“Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP, chief supply chain and operations officer of Bristol Myers Squibb, said in the release.
Shanahan said the facility uses flexible manufacturing and advanced technology to reliably deliver high-quality medicines.
Gov. Greg Abbott called Texas a global life sciences hub driving the future of healthcare.
“This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities,” Abbott said in the release. “With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”